JP2012525399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525399A5 JP2012525399A5 JP2012508609A JP2012508609A JP2012525399A5 JP 2012525399 A5 JP2012525399 A5 JP 2012525399A5 JP 2012508609 A JP2012508609 A JP 2012508609A JP 2012508609 A JP2012508609 A JP 2012508609A JP 2012525399 A5 JP2012525399 A5 JP 2012525399A5
- Authority
- JP
- Japan
- Prior art keywords
- tocotrienol
- alpha
- pharmaceutical composition
- composition according
- hydroquinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 36
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 24
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 24
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 22
- LNOVHERIIMJMDG-KTWAZNHYSA-N 2-[(6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LNOVHERIIMJMDG-KTWAZNHYSA-N 0.000 claims description 17
- 229930003802 tocotrienol Natural products 0.000 claims description 15
- 239000011731 tocotrienol Substances 0.000 claims description 15
- 235000019148 tocotrienols Nutrition 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 14
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 13
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 claims description 8
- 229940064063 alpha tocotrienol Drugs 0.000 claims description 7
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims description 7
- 235000019145 α-tocotrienol Nutrition 0.000 claims description 7
- 239000011730 α-tocotrienol Substances 0.000 claims description 7
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 claims description 6
- 210000003733 optic disk Anatomy 0.000 claims description 6
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 claims description 4
- 101150045559 Opa1 gene Proteins 0.000 claims description 4
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 claims description 4
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 claims description 4
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 claims description 4
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 claims description 4
- 208000001749 optic atrophy Diseases 0.000 claims description 4
- 235000019151 β-tocotrienol Nutrition 0.000 claims description 4
- 239000011723 β-tocotrienol Substances 0.000 claims description 4
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 claims description 4
- 235000019150 γ-tocotrienol Nutrition 0.000 claims description 4
- 239000011722 γ-tocotrienol Substances 0.000 claims description 4
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 claims description 4
- 206010033546 Pallor Diseases 0.000 claims description 3
- 206010043189 Telangiectasia Diseases 0.000 claims description 3
- 230000004456 color vision Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 230000004438 eyesight Effects 0.000 claims description 3
- 230000004298 light response Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 206010062198 microangiopathy Diseases 0.000 claims description 3
- 210000004126 nerve fiber Anatomy 0.000 claims description 3
- 210000002445 nipple Anatomy 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000001179 pupillary effect Effects 0.000 claims description 3
- 230000002207 retinal effect Effects 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 208000009056 telangiectasis Diseases 0.000 claims description 3
- 230000004304 visual acuity Effects 0.000 claims description 3
- SFVAYPRWECRHTF-QRCIITMISA-N 2-[(6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-6-methylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)(O)CCC1=CC(=O)C=C(C)C1=O SFVAYPRWECRHTF-QRCIITMISA-N 0.000 claims description 2
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 claims description 2
- 208000033707 Early-onset X-linked optic atrophy Diseases 0.000 claims description 2
- 101000722054 Homo sapiens Dynamin-like 120 kDa protein, mitochondrial Proteins 0.000 claims description 2
- 101000614988 Homo sapiens Mediator of RNA polymerase II transcription subunit 12 Proteins 0.000 claims description 2
- 101000640713 Homo sapiens Transmembrane protein 126A Proteins 0.000 claims description 2
- 102100021070 Mediator of RNA polymerase II transcription subunit 12 Human genes 0.000 claims description 2
- 102100033846 Transmembrane protein 126A Human genes 0.000 claims description 2
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 claims description 2
- 101150031431 opa gene Proteins 0.000 claims description 2
- 208000025019 optic atrophy 2 Diseases 0.000 claims description 2
- 208000009689 optic atrophy 4 Diseases 0.000 claims description 2
- 208000006042 optic atrophy 5 Diseases 0.000 claims description 2
- 208000006497 optic atrophy 6 Diseases 0.000 claims description 2
- 208000009606 optic atrophy 7 Diseases 0.000 claims description 2
- 210000001525 retina Anatomy 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 235000019144 δ-tocotrienol Nutrition 0.000 claims description 2
- 239000011729 δ-tocotrienol Substances 0.000 claims description 2
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000002775 capsule Substances 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 238000009472 formulation Methods 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21479509P | 2009-04-28 | 2009-04-28 | |
| US61/214,795 | 2009-04-28 | ||
| US31873310P | 2010-03-29 | 2010-03-29 | |
| US61/318,733 | 2010-03-29 | ||
| PCT/US2010/032624 WO2010126911A1 (en) | 2009-04-28 | 2010-04-27 | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226669A Division JP2015028084A (ja) | 2009-04-28 | 2014-11-07 | トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525399A JP2012525399A (ja) | 2012-10-22 |
| JP2012525399A5 true JP2012525399A5 (enExample) | 2013-07-11 |
Family
ID=42244195
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508609A Withdrawn JP2012525399A (ja) | 2009-04-28 | 2010-04-27 | トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 |
| JP2014226669A Withdrawn JP2015028084A (ja) | 2009-04-28 | 2014-11-07 | トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 |
| JP2016183749A Pending JP2016216506A (ja) | 2009-04-28 | 2016-09-21 | トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226669A Withdrawn JP2015028084A (ja) | 2009-04-28 | 2014-11-07 | トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 |
| JP2016183749A Pending JP2016216506A (ja) | 2009-04-28 | 2016-09-21 | トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100273894A1 (enExample) |
| EP (2) | EP2424495B1 (enExample) |
| JP (3) | JP2012525399A (enExample) |
| BR (1) | BRPI1013376A8 (enExample) |
| CA (1) | CA2777479C (enExample) |
| DK (1) | DK2424495T3 (enExample) |
| EA (1) | EA031126B1 (enExample) |
| ES (1) | ES2662051T3 (enExample) |
| HU (1) | HUE037574T2 (enExample) |
| MX (1) | MX336800B (enExample) |
| NO (1) | NO2424495T3 (enExample) |
| PL (1) | PL2424495T3 (enExample) |
| PT (1) | PT2424495T (enExample) |
| SI (1) | SI2424495T1 (enExample) |
| WO (1) | WO2010126911A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2583084C (en) | 2003-09-19 | 2010-12-07 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| EP2564842A1 (en) * | 2005-06-01 | 2013-03-06 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| CA2704473C (en) | 2007-11-06 | 2016-10-04 | Edison Pharmaceuticals, Inc. | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| EP2237664A4 (en) | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| MX363223B (es) | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| CA2974482C (en) | 2008-10-28 | 2019-10-29 | Bioelectron Technology Corporation | High purity alpha tocotrienol quinone and processes for preparing same |
| NO2424495T3 (enExample) | 2009-04-28 | 2018-06-16 | ||
| SI2470168T1 (en) * | 2009-08-26 | 2018-05-31 | Bioelectron Technology Corporation | Procedures for the prevention and treatment of brain ischemia |
| WO2011082355A1 (en) * | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| EP2642991A1 (en) | 2010-11-22 | 2013-10-02 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Therapeutical method for the treatment of the leber optic |
| WO2012174286A1 (en) * | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| US20150057363A1 (en) * | 2011-07-06 | 2015-02-26 | Guy M. Miller | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| RU2658461C2 (ru) | 2012-06-29 | 2018-06-21 | Рауф РЕКИК | Ингибиторы ангиотензинпревращающего фермента для лечения нейропатии зрительного нерва или врождённой атрофии зрительного нерва |
| EP2892515A1 (en) | 2012-09-07 | 2015-07-15 | Edison Pharmaceuticals, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
| EP2970158B1 (en) | 2013-03-15 | 2019-02-20 | BioElectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| WO2015103577A1 (en) * | 2014-01-06 | 2015-07-09 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating dominant optic atrophy |
| CN114702406B (zh) | 2014-12-16 | 2025-02-25 | Ptc医疗公司 | 化合物的多晶型和无定形形式 |
| MX2017015566A (es) * | 2015-06-05 | 2018-08-15 | Fundacio Hospital Univ Vall Dhebron Institut De Recerca | Tratamiento de enfermedades mitocondriales. |
| EP3390377A1 (en) | 2015-12-16 | 2018-10-24 | BioElectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| AU2016369616B2 (en) | 2015-12-17 | 2021-03-25 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| AU2019359381A1 (en) * | 2018-10-11 | 2021-04-29 | Imbria Pharmaceuticals, Inc. | Compositions and methods for treating and preventing Leber's hereditary optic neuropathy |
| RU2704013C1 (ru) * | 2019-04-18 | 2019-10-23 | ФГБНУ "НИИ глазных болезней" | Способ коррекции окислительного стресса при наследственной оптической нейропатии Лебера |
| CN112385783B (zh) | 2020-10-10 | 2022-07-05 | 南京农业大学 | 一种控制炭烤肉中多环芳烃含量的烤制方法 |
| WO2024259130A1 (en) * | 2023-06-16 | 2024-12-19 | Ptc Therapeutics, Inc. | Methods for increasing vatiquinone plasma exposure with food |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4875564A (enExample) | 1972-01-08 | 1973-10-11 | ||
| JPS4988862A (enExample) | 1972-12-29 | 1974-08-24 | ||
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| JPH0788376B2 (ja) | 1986-09-02 | 1995-09-27 | エーザイ株式会社 | 光学活性α−トコトリエノ−ルの製造方法 |
| US4914088A (en) | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| JP2685785B2 (ja) | 1988-03-11 | 1997-12-03 | エーザイ株式会社 | 光学活性α−トコトリエノールの製造方法 |
| JPH029875A (ja) | 1988-03-16 | 1990-01-12 | Bio Ind Kyokai | トコフェロール及びトコトリエノールの製造方法 |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| US5157132A (en) | 1990-05-18 | 1992-10-20 | Carotech Associates | Integrated process for recovery of carotenoids and tocotrienols from oil |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| DE69115990T2 (de) | 1990-05-29 | 1996-05-30 | Ocular Res Of Bonton Inc | Zusammensetzung zur Behandlung von Dry Eye Erkrankungen |
| ZA927277B (en) | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
| CA2124086A1 (en) | 1991-11-22 | 1993-05-27 | Ronald H. Lane | Tocotrienols and tocotrienol-like compounds and methods for their use |
| US5318993A (en) * | 1993-04-16 | 1994-06-07 | Bristol-Myers Squibb Company | Antihyperlipidemic benzoquinones |
| EP0708646A1 (en) | 1994-05-06 | 1996-05-01 | Alcon Laboratories, Inc. | Use of vitamin e tocopheryl derivatives in ophthalmic compositions |
| ES2176354T3 (es) | 1994-12-28 | 2002-12-01 | Janssen Pharmaceutica Nv | Uso de nebivolol como agente anti-aterogenico. |
| US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
| US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| WO1999038859A1 (en) | 1998-01-29 | 1999-08-05 | Eastman Chemical Company | Methods for separating a tocol from a tocol-containing mixture |
| WO2000078296A2 (en) | 1999-06-17 | 2000-12-28 | Basf Aktiengesellschaft | Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders |
| US6395915B1 (en) | 1999-09-10 | 2002-05-28 | Technikrom, Inc. | Method for producing purified tocotrienols and tocopherols using liquid chromatography |
| US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
| MY127451A (en) | 1999-11-04 | 2006-12-29 | Malaysian Palm Oil Board | A method of chromatographic isolation for vitamin e isomers |
| DE10034233A1 (de) | 2000-07-14 | 2002-01-24 | Basf Ag | Tocotrienolchinon-Cyclisierungsprodukte |
| GB0023555D0 (en) * | 2000-09-26 | 2000-11-08 | Inst Of Ophthalmology | Improvements in and relating to treatments for eye disease |
| US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| WO2002047680A2 (en) | 2000-12-15 | 2002-06-20 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
| US6838104B2 (en) | 2000-12-20 | 2005-01-04 | Archer Daniels Midland Company | Process for the production of tocotrienols |
| US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
| MXPA04001555A (es) | 2001-08-21 | 2004-10-27 | Galileo Pharmaceuticals Inc | Composiciones enriquecidas con tocoferol y mejoramiento de sintomas inflamatorios. |
| AU2002352726A1 (en) | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| US7078541B2 (en) | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
| US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| ATE328283T1 (de) | 2002-07-01 | 2006-06-15 | Santhera Pharmaceuticals Ch | Screeningverfahren und verbindungen zur behandlung von friedreich ataxia |
| JP4599292B2 (ja) | 2002-10-30 | 2010-12-15 | エジソン ファーマシューティカルズ， インコーポレイテッド | 物理的−化学的特性に基づく治療用化合物の同定 |
| US7015243B2 (en) * | 2003-08-28 | 2006-03-21 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
| CA2583084C (en) | 2003-09-19 | 2010-12-07 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| US20050074447A1 (en) * | 2003-10-01 | 2005-04-07 | Papas Andreas M. | Treatment for diabetic microvascular and macrovascular complications |
| WO2005035491A2 (en) | 2003-10-10 | 2005-04-21 | Yasoo Health, Inc. | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND |
| US8182990B2 (en) | 2004-03-18 | 2012-05-22 | Rusk Intellectual Reserve Ag | Method for diagnosing or predicting susceptibility to optic neuropathy |
| DE602004022523D1 (de) | 2004-07-02 | 2009-09-24 | Novagali Pharma Sa | Verwendung von Emulsionen zur intra- und periocularen Injection |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| ES2532997T3 (es) | 2005-04-22 | 2015-04-06 | Elizabeth Stuart | Uso de tocotrienoles de vitamina E para la inhibición del patógeno intracelular obligado Chlamydia |
| EP2564842A1 (en) * | 2005-06-01 | 2013-03-06 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| JP2009508867A (ja) | 2005-09-15 | 2009-03-05 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体 |
| CA2850858A1 (en) | 2005-09-16 | 2007-04-05 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
| JP5374162B2 (ja) * | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| CN101610782A (zh) | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱 |
| WO2008157747A1 (en) | 2007-06-21 | 2008-12-24 | The Jackson Laboratory | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders |
| US20100209436A1 (en) | 2007-07-03 | 2010-08-19 | Andreas Reichert | Method for treating diseases related to mitochondrial dysfunction |
| ES2507078T3 (es) | 2007-08-16 | 2014-10-14 | Santen Pharmaceutical Co., Ltd | Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad |
| US8075909B2 (en) | 2007-09-04 | 2011-12-13 | University Of Florida Research Foundation, Incorporated | Contact lens based bioactive agent delivery system |
| CA2704473C (en) | 2007-11-06 | 2016-10-04 | Edison Pharmaceuticals, Inc. | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| WO2009088572A2 (en) | 2008-01-07 | 2009-07-16 | Centocor, Inc. | Method of treating erythropoietin hyporesponsive anemias |
| EP2237664A4 (en) | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| US20110046156A1 (en) | 2008-03-05 | 2011-02-24 | Miller Guy M | Treatment of hearing and balance impairments with redox-active therapeutics |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| WO2009140382A2 (en) | 2008-05-15 | 2009-11-19 | Edison Pharmaceuticals, Inc. | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
| CA2724841A1 (en) | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| US8716486B2 (en) | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| US20100010100A1 (en) | 2008-07-09 | 2010-01-14 | Hinman Andrew W | Dermatological compositions with anti-aging and skin even-toning properties |
| US20100029784A1 (en) | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
| MX363223B (es) | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| JP5731980B2 (ja) | 2008-10-09 | 2015-06-10 | ラムズコア， インコーポレイテッド | ドライアイ症候群の処置のための組成物および方法 |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| CA2974482C (en) | 2008-10-28 | 2019-10-29 | Bioelectron Technology Corporation | High purity alpha tocotrienol quinone and processes for preparing same |
| NO2424495T3 (enExample) | 2009-04-28 | 2018-06-16 | ||
| US20100273892A1 (en) | 2009-04-28 | 2010-10-28 | Miller Guy M | Formulations of tocotrienol quinones for the treatment of ophthalmic diseases |
| JP2012525398A (ja) | 2009-04-28 | 2012-10-22 | アンペア ライフ サイエンシーズ，インコーポレイテッド | 眼科障害を治療するためのトコトリエノールの局所、眼周囲または眼内使用 |
| MX2011013558A (es) | 2009-06-25 | 2012-04-30 | Ampere Life Sciences Inc | Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos. |
| SI2470168T1 (en) | 2009-08-26 | 2018-05-31 | Bioelectron Technology Corporation | Procedures for the prevention and treatment of brain ischemia |
| WO2011041452A2 (en) | 2009-10-01 | 2011-04-07 | Ampere Life Sciences, Inc. | Mouse model for identifying compounds for the treatment of oxidative stress |
| WO2011082355A1 (en) | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
| EA201201374A1 (ru) | 2010-04-06 | 2013-04-30 | Эдисон Фармасьютикалз, Инк. | Лечение атаксии-телеангиэктазии |
| EP2563352A4 (en) | 2010-04-27 | 2013-11-13 | Edison Pharmaceuticals Inc | FORMULAS FROM CHINESE FOR THE TREATMENT OF EYE DISEASES |
| US20120101169A1 (en) | 2010-07-14 | 2012-04-26 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
| WO2012019032A1 (en) | 2010-08-06 | 2012-02-09 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
| US20130345312A1 (en) | 2010-08-06 | 2013-12-26 | Orion D. Jankowski | Treatment of mitochondrial diseases with naphthoquinones |
| US20120295985A1 (en) | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
| WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
| US20150057363A1 (en) | 2011-07-06 | 2015-02-26 | Guy M. Miller | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| EP2892515A1 (en) | 2012-09-07 | 2015-07-15 | Edison Pharmaceuticals, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
| JP6313791B2 (ja) | 2013-03-08 | 2018-04-18 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 皮膚科学的使用のためのレゾルシノール化合物 |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| EP2970158B1 (en) | 2013-03-15 | 2019-02-20 | BioElectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| WO2014194292A1 (en) | 2013-05-31 | 2014-12-04 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
-
2010
- 2010-04-27 NO NO10715650A patent/NO2424495T3/no unknown
- 2010-04-27 PL PL10715650T patent/PL2424495T3/pl unknown
- 2010-04-27 MX MX2011011309A patent/MX336800B/es active IP Right Grant
- 2010-04-27 HU HUE10715650A patent/HUE037574T2/hu unknown
- 2010-04-27 ES ES10715650.7T patent/ES2662051T3/es active Active
- 2010-04-27 SI SI201031630T patent/SI2424495T1/en unknown
- 2010-04-27 BR BRPI1013376A patent/BRPI1013376A8/pt not_active Application Discontinuation
- 2010-04-27 DK DK10715650.7T patent/DK2424495T3/en active
- 2010-04-27 WO PCT/US2010/032624 patent/WO2010126911A1/en not_active Ceased
- 2010-04-27 US US12/768,565 patent/US20100273894A1/en not_active Abandoned
- 2010-04-27 EP EP10715650.7A patent/EP2424495B1/en not_active Not-in-force
- 2010-04-27 PT PT107156507T patent/PT2424495T/pt unknown
- 2010-04-27 EP EP18151731.9A patent/EP3332766A1/en not_active Withdrawn
- 2010-04-27 EA EA201101575A patent/EA031126B1/ru not_active IP Right Cessation
- 2010-04-27 JP JP2012508609A patent/JP2012525399A/ja not_active Withdrawn
- 2010-04-27 CA CA2777479A patent/CA2777479C/en not_active Expired - Fee Related
-
2013
- 2013-04-09 US US13/859,592 patent/US9370496B2/en active Active
-
2014
- 2014-11-07 JP JP2014226669A patent/JP2015028084A/ja not_active Withdrawn
-
2016
- 2016-06-09 US US15/178,423 patent/US10195161B2/en not_active Expired - Fee Related
- 2016-09-21 JP JP2016183749A patent/JP2016216506A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525399A5 (enExample) | ||
| US9044439B2 (en) | Low dose lipoic and pharmaceutical compositions and methods | |
| ES2461617T3 (es) | Composiciones farmacéuticas acuosas que contienen complejos borato-polioles | |
| SI2424495T1 (en) | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones | |
| MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
| JP2012525397A5 (enExample) | ||
| JP2015526467A5 (enExample) | ||
| JP2010507686A5 (enExample) | ||
| KR20100067684A (ko) | 약물 전달을 위한 비히클로서의 수불혼화성 물질 | |
| EA200800056A1 (ru) | Каннабиноидный активный фармацевтический ингредиент для лекарственных форм | |
| JP2012525398A5 (enExample) | ||
| KR20000075894A (ko) | 소아과 수술에서의 레보부피바카인의 용도 | |
| JP2014508758A5 (enExample) | ||
| CN110678193A (zh) | 治疗和神经保护肽 | |
| TW201841635A (zh) | 用於治療抑鬱症之組合物及方法 | |
| RU2010154623A (ru) | Производные 1-аминоалкилциклогексана для лечения расстройств сна | |
| Reche-Frutos et al. | Retinal angiomatous proliferation reactivation 6 months after high-dose intravitreal acetonide triamcinolone and photodynamic therapy | |
| Hafez | Comparison of epithelium-off and transepithelial corneal collagen cross-linking for treatment of keratoconus | |
| Romano et al. | No retinal morphology changes after use of riboflavin and long‐wavelength ultraviolet light for treatment of keratoconus | |
| US9545409B2 (en) | Use of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof in pharmaceutical compositions as a neuroretinal protector | |
| ES2779525T3 (es) | Composición que comprende un éster de alfa-tocoferol para prevención y tratamiento de rinitis alérgica | |
| Higginbotham | Will latanoprost be the'wonder'drug of the'90s for the treatment of glaucoma? | |
| Hellman et al. | Dexamethasone 0.7 mg implant for the treatment of recalcitrant radiation maculopathy after proton radiotherapy for carcinoma of the maxillary sinus | |
| Pasyechnikova et al. | Serous pigment epithelium detachment associated with age-related macular degeneration: a possible treatment approach | |
| Romano et al. | Fluoxetine Protects Retinal Ischemic Damage in Mice. Pharmaceutics 2023, 15, 1370 |